July 20 - Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab, formerly LymphoStat-B®) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE).
Isn't it about time you offered us a valuation calculation based upon projected use of Arikace? Your comments on this issue are of no value to other users of this forum unless you can support your repeated claims that the current market valuation is reasonable with something more tangible than hot air.
FUD, as many have commented here, I too have no idea how to calculate our value. Why not ask Bo, or historian? These dudes seem to have their finger on the pulse of things.
look, I live in the real world...not fantasy land. The value of the company is what it is selling for today...right now. If you have skin in the game, the value is what one can sell it for....right now. Of course, we are all speculating, right?
I do think you have suggested a share price of up to $1,200....please correct me if I'm wrong. I just know this, it is what it is...you whining about insider trading and me whining about hedge fund activity will not change anything....if so, don't you think it would have changed something by now?
Perhaps you would be kind enough to give us your valuation and imeframe of such? You see, I'm an idiot about such specifics. I could use your help in determining what my percentage take will be. My buy price was $11.96.